Oral BPC-157 vs Injection: Capsules, Bioavailability, What Works

Key takeaways

• In rats, BPC-157 worked both injected and dissolved in drinking water, in ligament, colitis and fistula models. That is the entire basis for capsules.
• The 'stable in stomach acid' claim comes from the laboratory that discovered the peptide. An independent 2026 review accepts it but stresses that stability does not prove absorption.
• No human study has measured how much BPC-157 reaches the blood after a capsule or an under-the-skin injection. The only human blood-level data come from a two-person intravenous pilot whose method was not fully reported.
• A 2015 Phase 1 trial of oral tablets never reported results, and a 2026 gummy study lists no results either. What capsules contain has never been independently tested in a published study.
• Neither route is legal in the US in October 2026: no pharmacy may compound BPC-157 in any form, and a capsule sold to heal something is an unapproved drug, not a supplement.

The direct answer: nobody knows whether oral BPC-157 works in people, or how it compares with injections, because neither route has been tested properly in humans. In rats both routes healed experimental injuries, and the peptide is reported to survive stomach acid, which is why capsules exist. No human study has measured absorption from a capsule, and capsule contents are unverified. This is part of our review of peptides for gut health and inflammation; BPC-157 for gut health covers the gut studies by condition, and the BPC-157 profile has the full evidence, safety and legal history.

Oral versus injection, side by side

Where the 'stable in gastric juice' claim comes from

Most peptides are digested by stomach acid and pepsin within minutes, which is why almost all peptide drugs are injected. BPC-157 is different, according to the Zagreb laboratory that first described it in 1993. Its reviews describe the peptide as native to human gastric juice and not destroyed in it for more than 24 hours, and argue that this makes oral use straightforward (Sikiric 2024). Those statements cite the group's own earlier reviews; we could not find the original stability experiment as a standalone PubMed record.

An independent drug-development review published in 2026 accepts the stability as the peptide's most distinctive property, then explains why it settles less than sellers suggest (Mateescu 2026). A swallowed peptide must survive stomach acid, then intestinal enzymes, then cross the gut wall and pass the liver; gastric stability clears only the first barrier. The others have never been characterized for BPC-157, and approved oral peptides that act in the bloodstream needed substantial chemical or formulation work. Gastric stability, the review concludes, is necessary but not sufficient for oral bioavailability.

There is one scenario in which absorption does not matter: when the target is the gut lining itself. Linaclotide, an approved 14-amino-acid peptide for constipation-predominant IBS, is taken by mouth, acts on the surface of the intestinal lining, and is barely absorbed; its plasma levels are below the limit of measurement at approved doses (Linzess label). That is the most favorable reading of oral BPC-157 for the gut, and the rat data fit it; but linaclotide earned its label in randomized trials, and BPC-157 has none.

What the rats showed, route by route

In the ligament study, rats with a cut medial collateral ligament received BPC-157 once daily into the abdomen (10 mcg/kg or 10 ng/kg), as a thin cream on the injury, or in drinking water at 0.16 mcg per mL, about 12 mL a day, until the end of the 90-day study; all three routes improved functional, biomechanical and microscopic healing (Cerovecki 2010). In a colon-to-skin fistula model, the same two doses in drinking water or by injection both sped closure (Klicek 2008). Roughly 2 micrograms a day per rat in water matched the injected effect. That is the strongest argument for capsules, and it comes from one laboratory, in young rats treated from the hour of injury, with a dose-response so flat that micrograms and nanograms per kilogram gave the same result, which makes it hard to translate into any human dose.

The human pharmacokinetic gap

The only formal pharmacokinetic study of BPC-157, in rats and beagle dogs, tested intravenous and intramuscular dosing, not oral. The intact peptide had a half-life under 30 minutes, was broken down into small fragments and then ordinary amino acids, and left the body in urine and bile; intramuscular bioavailability was 14 to 19 percent in rats and 45 to 51 percent in dogs (He 2022). That species gap alone shows how uncertain any human prediction is.

In humans, the 2026 review counts one source of blood-level data: two people, aged 58 and 68, given 10 mg and then 20 mg by intravenous infusion. It reports a half-life under 30 minutes but notes that the laboratory method was not fully reported and that there was no oral or subcutaneous arm (Mateescu 2026). No human study has measured how much BPC-157 reaches the blood after a capsule, or after the under-the-skin injection sellers describe.

The oral trials that never reported

• 2015, oral tablets. A Croatian company registered a Phase 1 trial at a hospital in Tijuana: 42 healthy volunteers planned, single doses of one, three or six 1 mg tablets against placebo, then three tablets every eight hours for two weeks, with adverse events as the primary outcome and peak concentration, time to peak, exposure and half-life as secondary outcomes. The record was last updated in December 2015, its status is 'unknown', and no results were ever posted (NCT02637284).
• 2026, oral gummies. A supplement company registered an eight-week, single-arm study of its own BPC-157 gummy (labeled 500 mcg per serving, two gummies a day) in 40 physically active adults, with blood CRP and IL-6 and self-reported aches, stiffness and recovery as outcomes. It is listed as completed, with no results posted as of October 10, 2026 (NCT07752381). With no placebo group and no blood levels of the peptide, even a positive result could not show that the gummy works or that BPC-157 is absorbed.

What capsules contain is unverified

We found no published independent analysis of BPC-157 capsules or gummies. Labels list an amount, commonly 500 mcg and sometimes 1,000 mcg, but no pharmacy, regulator or published laboratory test stands behind the identity, quantity or purity of what is inside, and the 2026 review notes that no pharmaceutical-grade formulation of BPC-157 has been developed or validated in any form (Mateescu 2026). A capsule therefore adds a second unknown to the first: how much is in it, before the question of how much gets anywhere.

Legal status

BPC-157 has never been approved anywhere, and no US pharmacy may compound it in any form as of October 2026; the July 2026 committee vote in its favor has not been followed by a rule. Calling a capsule a 'supplement' changes nothing: a product sold to heal the gut, tendons or anything else is a drug, and FDA's 2026 warning letters rejected 'research use only' labels on peptides sold with dosing instructions. See the legal tracker, and our injection guide on why an unverified vial carries risks a pharmacy product does not.

Bottom line

Oral BPC-157 rests on two facts and one gap. The facts: it is reported to survive stomach acid, and it worked in rat drinking water. The gap: no human study has measured whether a capsule delivers anything, and the two registered oral studies have produced no results. Injection reaches the blood but has no human study of the under-the-skin route, and the peptide is gone in half an hour. For a gut target a local effect is plausible and untested; for anything else, a capsule asks you to assume an absorption nobody has shown. Neither route is legal to compound, and neither replaces treatment tested in people.

Frequently asked questions

+−Does oral BPC-157 work?

In rats, yes: BPC-157 dissolved in drinking water healed experimental ligament injuries, colitis and fistulas about as well as injections. In people, nobody knows. No human study has measured how much of a swallowed dose is absorbed, the one registered trial of oral tablets (2015) never reported results, and a 2026 study of a BPC-157 gummy has posted none either.

+−Is BPC-157 better taken orally or injected?

There is no human comparison of the two routes, so there is no evidence-based answer. The reasoning goes like this: for a gut target, a swallowed peptide that survives stomach acid could act directly on the gut lining, as it appears to in rats; for a tendon or joint, the peptide would have to reach the bloodstream, which has not been shown for oral BPC-157 in any species in a formal study. Injection gets it into the blood, but in animals the intact peptide is gone within about 30 minutes.

+−Can you take peptides orally?

Some, by design. Linaclotide, an approved 14-amino-acid peptide for constipation-predominant IBS, is swallowed and works on the gut lining while being barely absorbed. Most peptides are digested before they can do anything, and approved oral peptides meant to act elsewhere in the body needed special formulations. Whether a given peptide works by mouth has to be shown in trials, and for BPC-157 it has not been.

+−Does BPC-157 survive stomach acid?

The laboratory that discovered it says it is not destroyed in human gastric juice for more than 24 hours, and an independent 2026 review accepts that it is unusually stable. Stability is only the first hurdle: the peptide must also survive enzymes in the intestine and cross the gut wall to reach the blood, and no study has measured that in humans.

+−What is in BPC-157 capsules?

Whatever the seller put in them; no independent analysis of BPC-157 capsules has been published that we could find. Labels commonly state 500 mcg and sometimes 1,000 mcg per capsule, but no pharmacy or regulator checks the identity, amount or purity of what is sold as a research product or 'supplement'.

+−Are BPC-157 capsules a legal dietary supplement?

No. BPC-157 is an unapproved drug substance, and a product sold to heal the gut, tendons or anything else is a drug whatever its label says. No US pharmacy may compound BPC-157 in any form as of October 2026, and FDA's 2026 warning letters to peptide sellers rejected 'research use only' disclaimers on products sold with dosing instructions.

+−What oral dose of BPC-157 was studied?

In rats, 0.16 mcg per mL of drinking water, roughly 2 mcg a day per rat. In humans, a 2015 Phase 1 trial planned single doses of 1 to 6 mg in tablets and then 3 mg every eight hours for two weeks, but never reported results. Neither is a recommendation, and the 500 mcg capsules sold online match neither.

+−Does BPC-157 injection work better for gut problems?

There is no human evidence for either route in any gut condition. In rat colitis and fistula studies, drinking water and injection worked about equally, which fits a local effect on the gut lining. For anyone with a diagnosed gut condition, the treatments with human trials are the ones to start with.

Sources

1. StudyCerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010;28:1155-61. (2010)
2. StudyKlicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008;108:7-17. (2008)
3. ReviewSikiric P et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals (Basel) 2024;17:461. (2024)
4. StudyHe L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022;13:1026182. (2022)
5. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
6. SourceClinicalTrials.gov NCT02637284. Phase I pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02 (oral BPC-157 tablets): 42 participants planned, Mexico, 2015; status unknown, no results posted. (2015)
7. SourceClinicalTrials.gov NCT07752381. Single-arm study of BPC-157 gummies (500 mcg per serving, two gummies daily for 8 weeks) on hs-CRP, IL-6 and self-reported recovery in 40 physically active adults; first posted August 2026; completed, no results posted. (2026)
8. LabelLINZESS (linaclotide) capsules prescribing information, DailyMed, version of June 2026 (14-amino-acid peptide; minimally absorbed with negligible systemic availability; acts locally on the intestinal epithelium). (2026)